A $2.7 Billion Bet That a Simple Pill Can Fight Muscular Dystrophy
Servier just paid $1.55 billion upfront (with another $1.1 billion in milestones) for an oral pill that could become the first approved treatment for Becker muscular dystrophy. The pivotal trial data drop later this year, and analysts are modeling $2.2 billion in peak sales.
The Pill vs. the Disease Nobody Can Treat
There is no approved drug for Becker muscular dystrophy in the United States. Not one. Patients watch their muscles deteriorate year after year, and the best medicine can offer is steroids with a brutal side-effect profile: weight gain, bone loss, behavioral changes.
So when French pharma giant Servier agreed to pay up to $2.65 billion for Edgewise Therapeutics' muscular dystrophy business, the biotech world took notice. This isn't a gene therapy. It's not an injectable biologic. It's an oral tablet you swallow with a glass of water. And it could become the first disease-modifying treatment for a condition that has stumped drug developers for decades.
What Servier Is Actually Buying
The centerpiece of this deal is sevasemten (EDG-5506), a first-in-class small molecule that targets the root biomechanical problem in muscular dystrophy. Think of it this way: in Becker and Duchenne muscular dystrophy, patients lack enough dystrophin, a protein that acts like a shock absorber for muscle fibers. Every time a muscle contracts, it's like slamming a car without suspension over a pothole. The fibers tear, inflammation sets in, and scar tissue replaces functional muscle.
Sevasemten works by dialing down the force of contraction in fast-twitch muscle fibers. It selectively inhibits an enzyme called fast skeletal myosin ATPase, which is the molecular engine powering those contractions. Less force means less damage. Less damage means the muscle sticks around longer. It's not a cure; it's more like giving that beat-up car some actual shocks.
The deal structure breaks down into $1.55 billion in cash at closing and up to $1.1 billion in regulatory and commercial milestones. The transaction is expected to close in Q3 2026, pending regulatory clearance.
Importantly, Servier is not buying the whole company. Edgewise keeps its cardiovascular pipeline, including a cardiac program called EDG-7500. The $1.55 billion upfront payment, combined with Edgewise's existing cash, is expected to fund that heart program all the way through development and potential approval.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Data That Made Servier Write the Check
Sevasemten's clinical results so far tell a compelling story, even if the pivotal chapter hasn't been written yet.
In a Phase 1 trial with adults who have Becker muscular dystrophy, the drug slashed creatine kinase (a key marker of muscle damage) by roughly 70%. Fast skeletal muscle troponin I, another injury biomarker, dropped by 98%. No serious adverse events were reported, and nobody quit the trial because of side effects.
The longer-term data are even more interesting. In a two-year open-label study called ARCH, 12 adults with Becker muscular dystrophy took sevasemten daily. Their scores on the North Star Ambulatory Assessment (a standardized test of walking and movement ability) stayed stable over two years. In the natural history of the disease, patients typically lose about 2.4 points on that same scale over two years. Holding steady when you'd normally be declining is the kind of result that gets drug companies on the phone.
No one dropped out of the ARCH study due to side effects, either. For a disease where the standard of care (steroids) comes loaded with toxicity, tolerability matters enormously.
The big catalyst still ahead: results from GRAND CANYON, the pivotal global trial in Becker muscular dystrophy, are expected to read out this year. That's the data that will determine whether sevasemten can actually get approved.
What Wall Street Thinks (And Where the Risk Hides)
Analysts are broadly positive, but nobody's calling this a slam dunk.
RBC Capital Markets analyst Leonid Timashev called the sale a "prudent decision" for Edgewise, noting that it "greatly improves the company's cash position." He estimated peak annual sales of roughly $5–6 billion for sevasemten, and concluded that the deal is roughly "fair value neutral if all milestones are reached." In other words, Servier is paying close to the risk-adjusted value of the asset, not a wild premium.
Timashev also made an observation that explains the deal's logic from Edgewise's perspective: sevasemten had "striking data (particularly in Becker)," but it was "not necessarily fully valued by Street due to perceived risk and challenges in the space." Translation: the stock market wasn't giving Edgewise full credit for this drug, so cashing in made strategic sense.
Guggenheim Securities provided a more granular risk assessment, modeling a probability of success for sevasemten in Becker muscular dystrophy and just 25% in Duchenne. The Becker odds reflect solid proof-of-concept data; the Duchenne estimate reflects a much earlier, less proven program. Guggenheim's team said they "remained confident in a statistically significant outcome" for the GRAND CANYON trial, which will be the moment of truth.
Why Servier, and Why Now
This deal makes more sense when you zoom out on Servier's strategy. The company has explicitly identified neuromuscular disorders as one of six priority clusters within a new neurology franchise it's building toward 2030. Its wish list includes ALS, SMA, myasthenia gravis, and multiple forms of muscular dystrophy.
Servier has been on a buying spree to build this franchise from the outside in. Its first neurology asset acquisition was KER-0193 for Fragile X syndrome, valued at up to $450 million. The sevasemten deal is significantly larger and signals an escalation in ambition.
The company described the acquisition as a move that could make it a "global player with strong capabilities" in neuromuscular disorders. That's corporate-speak, sure, but the price tag backs it up.
The Bigger Picture for Muscular Dystrophy
For years, muscular dystrophy drug development has been dominated by gene therapies and exon-skipping approaches (drugs that trick cells into reading past genetic mutations). These are clever technologies, but they come with significant limitations. Gene therapies are one-time, expensive, and logistically complex. Exon-skipping drugs only work for patients with specific mutations, leaving many people out.
Sevasemten represents a fundamentally different approach. It doesn't try to fix the broken gene. Instead, it reduces the mechanical consequences of having a broken gene. Because it works regardless of mutation type, it could theoretically treat a much broader patient population.
For context, the biggest neuromuscular deal of recent years was Novartis's $12 billion acquisition of Avidity Biosciences in 2025, which brought in an RNA-based platform for muscular dystrophies. Servier's deal is smaller, but it's notable for betting on a simple oral pill in a space dominated by complex biologics.
If GRAND CANYON delivers positive data later this year, Servier will own the rights to what could be the first approved treatment for Becker muscular dystrophy, period. For a disease that's been waiting this long, that's not just a business story. It's a human one.
Clinical & Regulatory4 min read
The FDA Just Killed a Sickle Cell Drug — in Biotech's Hottest Market
Fulcrum Therapeutics' sickle cell drug showed real promise, but the FDA shut it down over cancer fears tied to an entire drug class. The stock cratered 50%, the company's only clinical program vanished, and the implications stretch far beyond one biotech.
